Immunogenicity and protective efficacy of heterologous prime-boost regimens with mycobacterial vaccines and recombinant adenovirus- and poxvirus-vectored vaccines against murine tuberculosis

International Journal of Infectious Diseases

Volumn 16, Issue 11, 2012, Pages

  You, Qingrui ^a   Wu, Yongge ^a   Wu, Yang ^a   Wei, Wei ^a   Wang, Changyong ^a   Jiang, Dehua ^a   Yu, Xianghui ^a   Zhang, Xizhen ^a   Wang, Yong ^b   Tang, Zhijiao ^b   Jiang, Chunlai ^a   Kong, Wei ^a  

^a JILIN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

Adenovirus; Boost vaccine; MVA (modified vaccinia virus Ankara); Tuberculosis

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; RECOMBINANT VACCINE; VIRUS VACCINE; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GRANULOMA; HELPER CELL; HISTOPATHOLOGY; HUMORAL IMMUNITY; IMMUNOGENICITY; LUNG TUBERCULOSIS; MOUSE; NONHUMAN; POXVIRUS; TH1 CELL; VACCINATION;

ANIMALS; ANTIBODIES, BACTERIAL; BCG VACCINE; CYTOTOXICITY TESTS, IMMUNOLOGIC; FEMALE; GENETIC VECTORS; HISTOCYTOCHEMISTRY; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; SPECIFIC PATHOGEN-FREE ORGANISMS; TH1 CELLS; TUBERCULOSIS; VACCINES, SYNTHETIC;

EID: 84868208032     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2012.07.008     Document Type: Article

References (72)

1. Global tuberculosis control 2011 2011, World Health Organization, WHO, Geneva.
2. Tseng C.L., Oxlade O., Menzies D., Aspler A., Schwartzman K. Cost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study. BMC Public Health 2011, 11:55.
3. Brewer T.F. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clin Infect Dis 2000, 31(Suppl 3):S64-S67.
4. Tala-Heikkila M.M., Tuominen J.E., Tala E.O. Bacillus Calmette-Guerin revaccination questionable with low tuberculosis incidence. Am J Respir Crit Care Med 1998, 157:1324-1327.
5. Buddle B.M., Wedlock D.N., Parlane N.A., Corner L.A., De Lisle G.W., Skinner M.A. Revaccination of neonatal calves with Mycobacterium bovis BCG reduces the level of protection against bovine tuberculosis induced by a single vaccination. Infect Immun 2003, 71:6411-6419.
6. Basaraba R.J., Izzo A.A., Brandt L., Orme I.M. Decreased survival of guinea pigs infected with Mycobacterium tuberculosis after multiple BCG vaccinations. Vaccine 2006, 24:280-286.
7. Ramshaw I.A., Ramsay A.J. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 2000, 21:163-165.
8. Xing Z., Charters T.J. Heterologous boost vaccines for bacillus Calmette-Guerin prime immunization against tuberculosis. Expert Rev Vaccines 2007, 6:539-546.
9. Rouanet C., Locht C. Boosting BCG to protect against TB. Expert Rev Respir Med 2010, 4:339-348.
10. Andersen C.S., Dietrich J., Agger E.M., Lycke N.Y., Lovgren K., Andersen P. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infect Immun 2007, 75:408-416.
11. Palma C., Iona E., Giannoni F., Pardini M., Brunori L., Fattorini L., et al. The LTK63 adjuvant improves protection conferred by Ag85B DNA-protein prime-boosting vaccination against Mycobacterium tuberculosis infection by dampening IFN-gamma response. Vaccine 2008, 26:4237-4243.
12. Aagaard C., Hoang T., Dietrich J., Cardona P.J., Izzo A., Dolganov G., et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 2011, 17:189-194.
13. McShane H., Pathan A.A., Sander C.R., Goonetilleke N.P., Fletcher H.A., Hill A.V. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinb) 2005, 85:47-52.
14. Pathan A.A., Sander C.R., Fletcher H.A., Poulton I., Alder N.C., Beveridge N.E., et al. Boosting BCG with recombinant modified vaccinia Ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials. PLoS ONE 2007, 2:e1052.
15. Santosuosso M., McCormick S., Zhang X., Zganiacz A., Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect Immun 2006, 74:4634-4643.
16. Wang J., Zganiacz A., Xing Z. Enhanced immunogenicity of BCG vaccine by using a viral-based GM-CSF transgene adjuvant formulation. Vaccine 2002, 20:2887-2898.
17. Derrick S.C., Yang A.L., Morris S.L. A polyvalent DNA vaccine expressing an ESAT6-Ag85B fusion protein protects mice against a primary infection with Mycobacterium tuberculosis and boosts BCG-induced protective immunity. Vaccine 2004, 23:780-788.
18. Bennekov T., Dietrich J., Rosenkrands I., Stryhn A., Doherty T.M., Andersen P. Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis. Eur J Immunol 2006, 36:3346-3355.
19. McShane H., Behboudi S., Goonetilleke N., Brookes R., Hill A.V. Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8(+)- and CD4(+)-T-cell epitopes from antigen 85A. Infect Immun 2002, 70:1623-1626.
20. Wang J., Thorson L., Stokes R.W., Santosuosso M., Huygen K., Zganiacz A., et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 2004, 173:6357-6365.
21. Perera P.Y., Derrick S.C., Kolibab K., Momoi F., Yamamoto M., Morris S.L., et al. A multi-valent vaccinia virus-based tuberculosis vaccine molecularly adjuvanted with interleukin-15 induces robust immune responses in mice. Vaccine 2009, 27:2121-2127.
22. Xing Z., Santosuosso M., McCormick S., Yang T.C., Millar J., Hitt M., et al. Recent advances in the development of adenovirus- and poxvirus-vectored tuberculosis vaccines. Curr Gene Ther 2005, 5:485-492.
23. Horwitz M.A., Harth G., Dillon B.J., Maslesa-Galic S. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci U S A 2000, 97:13853-13858.
24. Grode L., Seiler P., Baumann S., Hess J., Brinkmann V., Nasser Eddine A., et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 2005, 115:2472-2479.
25. Sun R., Skeiky Y.A., Izzo A., Dheenadhayalan V., Imam Z., Penn E., et al. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 2009, 27:4412-4423.
26. Horwitz M.A., Harth G., Dillon B.J., Maslesa-Galic S. A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG. Vaccine 2006, 24:1593-1600.
27. Horwitz M.A., Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun 2003, 71:1672-1679.
28. Horwitz M.A. Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins. Microbes Infect 2005, 7:947-954.
29. You Q., Jiang C., Wu Y., Yu X., Chen Y., Zhang X., et al. Subcutaneous administration of modified vaccinia virus Ankara expressing an Ag85B-ESAT6 fusion protein, but not an adenovirus-based vaccine, protects mice against intravenous challenge with Mycobacterium tuberculosis. Scand J Immunol 2012, 75:77-84.
30. You Q., Wu Y., Jiang D., Wang C., Wei W., Yu X., et al. Immune responses induced by heterologous boosting of recombinant bacillus Calmette-Guerin with Ag85B-ESAT6 fusion protein in levamisole-based adjuvant. Immunol Invest 2012, 41:412-428.
31. Radosevic K., Wieland C.W., Rodriguez A., Weverling G.J., Mintardjo R., Gillissen G., et al. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect Immun 2007, 75:4105-4115.
32. D'Souza S., Rosseels V., Romano M., Tanghe A., Denis O., Jurion F., et al. Mapping of murine Th1 helper T-cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis. Infect Immun 2003, 71:483-493.
33. Denis O., Tanghe A., Palfliet K., Jurion F., van den Berg T.P., Vanonckelen A., et al. Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4+and CD8+T-cell epitopic repertoire broader than that stimulated by Mycobacterium tuberculosis H37Rv infection. Infect Immun 1998, 66:1527-1533.
34. Brandt L., Oettinger T., Holm A., Andersen A.B., Andersen P. Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis. J Immunol 1996, 157:3527-3533.
35. Olsen A.W., Hansen P.R., Holm A., Andersen P. Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen. Eur J Immunol 2000, 30:1724-1732.
36. Jellison E.R., Kim S.K., Welsh R.M. Cutting edge: MHC class II-restricted killing in vivo during viral infection. J Immunol 2005, 174:614-618.
37. Stevens T.L., Bossie A., Sanders V.M., Fernandez-Botran R., Coffman R.L., Mosmann T.R., et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 1988, 334:255-258.
38. Russell D.G., Barry C.E., Flynn J.L. Tuberculosis: what we don't know can, and does, hurt us. Science 2010, 328:852-856.
39. Rollier C.S., Reyes-Sandoval A., Cottingham M.G., Ewer K., Hill A.V. Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol 2011, 23:377-382.
40. Liu M.A. Immunologic basis of vaccine vectors. Immunity 2010, 33:504-515.
41. Brave A., Ljungberg K., Wahren B., Liu M.A. Vaccine delivery methods using viral vectors. Mol Pharm 2007, 4:18-32.
42. North R.J., Jung Y.J. Immunity to tuberculosis. Annu Rev Immunol 2004, 22:599-623.
43. Mu J., Jeyanathan M., Small C.L., Zhang X., Roediger E., Feng X., et al. Immunization with a bivalent adenovirus-vectored tuberculosis vaccine provides markedly improved protection over its monovalent counterpart against pulmonary tuberculosis. Mol Ther 2009, 17:1093-1100.
44. Rosenkrands I., Agger E.M., Olsen A.W., Korsholm K.S., Andersen C.S., Jensen K.T., et al. Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system. Infect Immun 2005, 73:5817-5826.
45. Geiben-Lynn R., Greenland J.R., Frimpong-Boateng K., Letvin N.L. Kinetics of recombinant adenovirus type 5, vaccinia virus, modified vaccinia Ankara virus, and DNA antigen expression in vivo and the induction of memory T-lymphocyte responses. Clin Vaccine Immunol 2008, 15:691-696.
46. Barry M., Bleackley R.C. Cytotoxic Tlymphocytes: all roads lead to death. Nat Rev Immunol 2002, 2:401-409.
47. Sergeev R.A., Batorsky R.E., Rouzine I.M. Model with two types of CTL regulation and experiments on CTL dynamics. J Theor Biol 2010, 263:369-384.
48. Williams M.A., Bevan M.J. Effector and memory CTL differentiation. Annu Rev Immunol 2007, 25:171-192.
49. Agger E.M., Andersen P. Tuberculosis subunit vaccine development: on the role of interferon-gamma. Vaccine 2001, 19:2298-2302.
50. Mittrucker H.W., Steinhoff U., Kohler A., Krause M., Lazar D., Mex P., et al. Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis. Proc Natl Acad Sci U S A 2007, 104:12434-12439.
51. Goldsack L., Kirman J.R. Half-truths and selective memory: interferon gamma, CD4(+) T cells and protective memory against tuberculosis. Tuberculosis (Edinb) 2007, 87:465-473.
52. Skinner M.A., Ramsay A.J., Buchan G.S., Keen D.L., Ranasinghe C., Slobbe L., et al. A DNA prime-live vaccine boost strategy in mice can augment IFN-gamma responses to mycobacterial antigens but does not increase the protective efficacy of two attenuated strains of Mycobacterium bovis against bovine tuberculosis. Immunology 2003, 108:548-555.
53. Lindenstrom T., Agger E.M., Korsholm K.S., Darrah P.A., Aagaard C., Seder R.A., et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol 2009, 182:8047-8055.
54. Beveridge N.E., Price D.A., Casazza J.P., Pathan A.A., Sander C.R., Asher T.E., et al. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+memory T lymphocyte populations. Eur J Immunol 2007, 37:3089-3100.
55. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007, 13:843-850.
56. Reyes-Sandoval A., Wyllie D.H., Bauza K., Milicic A., Forbes E.K., Rollier C.S., et al. CD8+T effector memory cells protect against liver-stage malaria. J Immunol 2011, 187:1347-1357.
57. Yang T.C., Millar J., Groves T., Grinshtein N., Parsons R., Takenaka S., et al. The CD8+T cell population elicited by recombinant adenovirus displays a novel partially exhausted phenotype associated with prolonged antigen presentation that nonetheless provides long-term immunity. J Immunol 2006, 176:200-210.
58. Harrington L.E., van der Most R., Whitton J.L., Ahmed R. Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J Virol 2002, 76:3329-3337.
59. Reyes-Sandoval A., Berthoud T., Alder N., Siani L., Gilbert S.C., Nicosia A., et al. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+T-cell responses. Infect Immun 2010, 78:145-153.
60. Tatsis N., Lin S.W., Harris-McCoy K., Garber D.A., Feinberg M.B., Ertl H.C. Multiple immunizations with adenovirus and MVA vectors improve CD8+T cell functionality and mucosal homing. Virology 2007, 367:156-167.
61. Palendira U., Spratt J.M., Britton W.J., Triccas J.A. Expanding the antigenic repertoire of BCG improves protective efficacy against aerosol Mycobacterium tuberculosis infection. Vaccine 2005, 23:1680-1685.
62. Mathurin K.S., Martens G.W., Kornfeld H., Welsh R.M. CD4 T-cell-mediated heterologous immunity between mycobacteria and poxviruses. J Virol 2009, 83:3528-3539.
63. Ota M.O., Odutola A.A., Owiafe P.K., Donkor S., Owolabi O.A., Brittain N.J., et al. Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants. Sci Transl Med 2011, 3:88ra56.
64. Joosten S.A., van Meijgaarden K.E., Savage N.D., de Boer T., Triebel F., van der Wal A., et al. Identification of a human CD8+regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4. Proc Natl Acad Sci U S A 2007, 104:8029-8034.
65. Belkaid Y., Rouse B.T. Natural regulatory T cells in infectious disease. Nat Immunol 2005, 6:353-360.
66. Santosuosso M., McCormick S., Roediger E., Zhang X., Zganiacz A., Lichty B.D., et al. Mucosal luminal manipulation of T cell geography switches on protective efficacy by otherwise ineffective parenteral genetic immunization. J Immunol 2007, 178:2387-2395.
67. Goonetilleke N.P., McShane H., Hannan C.M., Anderson R.J., Brookes R.H., Hill A.V. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 2003, 171:1602-1609.
68. North R.J. Mycobacterium tuberculosis is strikingly more virulent for mice when given via the respiratory than via the intravenous route. J Infect Dis 1995, 172:1550-1553.
69. Jeyanathan M., Heriazon A., Xing Z. Airway luminal T cells: a newcomer on the stage of TB vaccination strategies. Trends Immunol 2010, 31:247-252.
70. Holt P.G., Strickland D.H., Wikstrom M.E., Jahnsen F.L. Regulation of immunological homeostasis in the respiratory tract. Nat Rev Immunol 2008, 8:142-152.
71. Roediger E.K., Kugathasan K., Zhang X., Lichty B.D., Xing Z. Heterologous boosting of recombinant adenoviral prime immunization with a novel vesicular stomatitis virus-vectored tuberculosis vaccine. Mol Ther 2008, 16:1161-1169.
72. Capone S., Reyes-Sandoval A., Naddeo M., Siani L., Ammendola V., Rollier C.S., et al. Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. Vaccine 2010, 29:256-265.